Highest Response in Metastatic Renal-Cell Carcinoma with Pazopanib, Third-Line VEGF Inhibitor

VBCC - May 2014 Vol 5, No 4 - AACR Annual Meeting
Charles Bankhead

San Diego, CA—Almost 50% of patients with metastatic renal-cell carcinoma (mRCC) had objective responses to third-line treatment with the angiogenesis inhibitor pazopanib, according to the results of a small clinical trial reported at the 2014 American Association for Cancer Research annual meeting.

Overall, 12 of 28 patients achieved objective responses (including 1 complete response), and another patient had an unconfirmed partial response. In the subgroup of responding patients, the duration of response to pazopanib exceeded the duration of previous responses in a majority of cases.

The cohort had a median progression-free survival of 16.5 months, a “remarkable” clinical outcome for such a heavily pretreated group of patients, said principal investigator Sumanta K. Pal, MD, Assistant Professor of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA.

“This is the highest objective response rate observed to date in a trial of third-line therapy for metastatic renal-cell carcinoma,” said Dr Pal. “Equally unprecedented is the median progression-free survival, which is remarkable for this group of patients.”

Pazopanib, a multitargeted tyrosine kinase inhibitor, is approved for the treatment of advanced RCC. Previous studies of the agent included a phase 3 trial of patients who were refractory to cytokine therapy or were treatment-naïve. No previous trial had determined pazopanib’s activity in the third-line setting or examined temporal changes in molecular profile during therapy.

Study Details
Dr Pal and colleagues evaluated pazopanib’s third-line potential for mRCC in a well-defined group of previously treated patients. They performed a phase 2, single-arm trial involving patients whose disease had progressed after 2 previous systemic regimens, 1 of which had to be an inhibitor of vascular endothelial growth factor (VEGF). Other eligibility criteria included Eastern Cooperative Oncology Group performance status of 0 to 2, and clear-cell histology.

The primary outcome was response rate, and the trial was statistically powered to detect a 23% overall response rate, defined as “clinically encouraging.” Investigators also examined immunologic markers associated with treatment failure or success.

Patients received pazopanib 800 mg daily on 28-day cycles. Treatment continued until disease progression, unacceptable toxicity, or death.

None of the patients enrolled in the study had good-risk characteristics. Approximately 60% had intermediate-risk features, and approximately 40% had poor-risk features.

Overall, 23 of the 28 patients received anti-VEGF therapy as first-line treatment, and the most frequently used therapy in second-line was the mammalian target of rapamycin inhibitor class. Some of the patients received anti-VEGF therapy as first- and second-line therapy. The median duration of previous anti-VEGF therapy was 4 months.

In addition to the 13 patients who had responses (including the 1 unconfirmed response), 9 had stable disease, resulting in a clinical benefit rate of 78%. After a median follow-up of 17.1 months, the median overall survival had yet to be reached.

Biomarker analysis showed that response was associated with lower levels of hepatocyte growth factor, VEGF, interleukin (IL)-8, IL-6, and soluble IL-2 receptor (P <.05 for all analyses).

The most frequently reported adverse event was hypertension (93%, all grades), which was grade 3/4 in 50% of the cases. Blood pressure was manageable with antihypertensive medications, and no patient stopped treatment because of uncontrolled blood pressure.

In addition, 14% of patients had grade 3 proteinuria. The most frequently reported laboratory abnormalities were hyponatremia and elevated creatinine.

Related Items
Loss of Independence Common Even in Early-Stage Parkinson’s Disease
Charles Bankhead
VBCN - November 2016 Volume 3, No 3 published on November 22, 2016 in Parkinson’s Disease
One-Fourth of Eligible Patients with Stroke Still Not Receiving Thrombolytic Therapy
Charles Bankhead
VBCN - November 2016 Volume 3, No 3 published on November 22, 2016 in Stroke
Timing of Epilepsy Onset Influences Type of Cognitive Impairment and Memory Deficits
Charles Bankhead
VBCN - November 2016 Volume 3, No 3 published on November 22, 2016 in Epilepsy/Seizures
Characteristics of “Superutilizers” Among Patients with Schizophrenia
Charles Bankhead
VBCN - November 2016 Volume 3, No 3 published on November 22, 2016 in Schizophrenia
More Evidence of Increased Mortality Risk in Patients with Rheumatoid Arthritis
Charles Bankhead
VBCR - October 2016, Vol 5, No 5 published on November 2, 2016 in Rheumatoid Arthritis
Creatine Boosts Muscle in Rheumatoid Arthritis, but Not Strength or Function
Charles Bankhead
VBCR - August 2016, Vol 5, No 4 published on August 25, 2016 in Rheumatoid Arthritis
Mixed Cost Results with Repository Corticotropin Injection Therapy for Patients with SLE
Charles Bankhead
VBCR - August 2016, Vol 5, No 4 published on August 25, 2016 in Lupus
Mutation Testing Encouraged for All Patients with Ovarian Cancer
Charles Bankhead
VBCC - June 2016, Vol 7, No 5 published on June 17, 2016 in Personalized Medicine
Chemotherapy Use in Breast Cancer Declines with Gene-Based Assay
Charles Bankhead
VBCC - June 2016, Vol 7, No 5 published on June 17, 2016 in Value in Oncology
Novel Regimen Outperforms Standard Chemotherapy in HER2 Breast Cancer
Charles Bankhead
VBCC - June 2016, Vol 7, No 5 published on June 17, 2016 in Breast Cancer
Last modified: May 28, 2014
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology